IEQ Capital’s Anika Therapeutics ANIK Stock Holding History

IEQ Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$285K	Buy	19,678 +9,609	+95%	+$112K	﹤0.01%	1535
2025 Q4	$96.8K	Buy	+10,069	New	+$96.4K	﹤0.01%	1764

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IEQ Capital's ANIK Position: Q1 2026 in Review

IEQ Capital increased its Anika Therapeutics (ANIK) stake by 95% in Q1 2026, buying an estimated $112K and bringing the position to 19,678 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

IEQ Capital first reported a position in ANIK in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

IEQ Capital held 19,678 shares of Anika Therapeutics worth $285K as of Q1 2026.
IEQ Capital bought 9,609 Anika Therapeutics shares in Q1 2026, an estimated $112K.
Anika Therapeutics made up ﹤0.01% of IEQ Capital's portfolio in Q1 2026, its #1535 holding.
IEQ Capital first reported a position in Anika Therapeutics in Q4 2025 and has held it in 2 quarters since.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.